RT - Article
SR - Electronic
T1 - 
SP - 2018-01-11
A1 - Дьяконов, В.А., 
A1 - Джемилева, Л.У., 
A1 - Макаров, А.А., 
A1 - Мулюкова, А.Р., 
A1 - Хуснутдинова, Э.К., 
A1 - Джемилев, У.М., 
A1 - Толстикова Т. Г., 
A1 - , 
A1 - , 
A1 - , 
A1 - , 
A1 - , 
A1 - , 
A1 - , 
YR - 2015
UL - https://repo.bashgmu.ru/publication/597
AB - (5Z,9Z)-11-Phenylundeca-5,9-dienoic acid was stereoselectively synthesized,
based on original cross-cyclomagnesiation of 2-(hepta-5,6-dien-1-yloxy)tetrahydro-2H-pyran and buta-2,3-dien-1-ylbenzene with
EtMgBr in the presence of the Cp2TiCl2 catalyst giving 2,5-dialkylydenemagnesacyclopentane in 86% yield. The acid hydrolysis
of the product and Jones oxidation of the resulting 2-{[(5Z,9Z)-11-phenylundeca-5,9-dien-1-yl]oxy}tetrahydro-2Н-pyran
afforded (5Z,9Z)-11-phenylundeca-5,9-dienoic acid in an overall yield of 75%. A high inhibitory activity of the
synthesized acid with respect to human topoisomerase I (hTop1) and II (hTop2α) was detected. Resorting to the data of
molecular docking, a mechanism of inhibition was proposed.